US green light for AZ’ Lokelma
US regulators have finally issued a green light for AstraZeneca’s Lokelma as a treatment for hyperkalaemia – elevated potassium levels in the blood – in adult patients.
Read More
Tag: RAAS
EU nod for Vifor’s Veltassa
European regulators have approved Vifor Pharma’s new potassium binder Veltassa to treat hyperkalaemia in adult patients.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
